BioNTech SE (NASDAQ:BNTX) Shares Purchased by CANADA LIFE ASSURANCE Co

CANADA LIFE ASSURANCE Co boosted its position in BioNTech SE (NASDAQ:BNTX - Free Report) by 63.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,791 shares of the company's stock after purchasing an additional 3,025 shares during the quarter. CANADA LIFE ASSURANCE Co's holdings in BioNTech were worth $887,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in BNTX. FMR LLC raised its stake in BioNTech by 22.2% in the 4th quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after purchasing an additional 1,401,547 shares during the last quarter. abrdn plc raised its stake in BioNTech by 70.7% in the 4th quarter. abrdn plc now owns 385,668 shares of the company's stock valued at $43,947,000 after purchasing an additional 159,676 shares during the last quarter. Franklin Resources Inc. raised its stake in BioNTech by 3,942.1% in the 4th quarter. Franklin Resources Inc. now owns 136,786 shares of the company's stock valued at $15,587,000 after purchasing an additional 133,402 shares during the last quarter. CenterBook Partners LP raised its stake in BioNTech by 62.5% in the 4th quarter. CenterBook Partners LP now owns 194,118 shares of the company's stock valued at $22,120,000 after purchasing an additional 74,656 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of BioNTech in the 4th quarter worth $7,128,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Stock Performance

Shares of BioNTech stock opened at $104.00 on Wednesday. The business has a 50-day moving average of $101.14 and a 200 day moving average of $110.38. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The stock has a market capitalization of $24.96 billion, a price-to-earnings ratio of -49.52 and a beta of 1.07. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.70. The business had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business's quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.90 EPS. As a group, sell-side analysts forecast that BioNTech SE will post -3.88 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on BNTX shares. Truist Financial started coverage on BioNTech in a research note on Friday, January 10th. They issued a "buy" rating and a $172.00 target price for the company. Morgan Stanley cut their target price on BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a research note on Tuesday, March 11th. BMO Capital Markets raised their target price on BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 11th. HC Wainwright cut their target price on BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $171.44 target price on shares of BioNTech in a research note on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $143.44.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.